National Coverage Determination 200.3: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

MLN Matters Number: MM12950
Related CR Release Date: November 9, 2022
Related CR Transmittal Number: R11692
Related Request (CR) Number: 12950
Effective Date: April 7, 2022
NCD Implementation Date: December 12, 2022

CR 12950 tells you about:

  • FDA-approved monoclonal antibodies
  • CMS-approved studies

Make sure your billing staff knows about these changes.

View the complete CMS Medicare Learning Network (MLN) Matters (MM)12950.

Last Updated Dec 14 , 2022